Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456393 | 0.97 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL38652354 | 0.93 | SLC6A2 (0.55) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL29390515 | 0.92 | OPRM1 (0.52) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL30480492 | 0.91 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL30480493 | 0.91 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL31127558 | 0.91 | F2 (0.60) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL6516908 | 0.91 | REN (0.58) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL29525618 | 0.91 | REN (0.58) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL10522787 | 0.90 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC6A2REN | |
| SCHEMBL30729666 | 0.89 | SLC6A2 (0.52) | OPRM1OPRD1OPRK1SLC6A2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250320471-A1 | Method for Producing Compounds, Method for Producing Compound Library, Compound Library, and Screening Method | UNIV TOKYO (JP) | 2025-10-16 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022238734-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | OPRM1 988/4885OPRD1 1329/4885OPRK1 938/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | OPRM1 988/4885OPRD1 1329/4885OPRK1 938/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | OPRM1 3210/4885OPRD1 2958/4885OPRK1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.